- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.07. | Gain Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 16.07. | Gain Therapeutics plans phase 2 Parkinson's study in Q3 2026 | 1 | Investing.com | ||
| 16.07. | Gain Therapeutics plant Phase-2-Studie zu Parkinson für drittes Quartal 2026 | 1 | Investing.com Deutsch | ||
| 16.07. | Gain Therapeutics, Inc.: Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update | 303 | GlobeNewswire (Europe) | BETHESDA, Md., July 16, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of... ► Artikel lesen | |
| 01.07. | H.C. Wainwright reiterates Gain Therapeutics stock rating on FDA approval | 3 | Investing.com | ||
| 29.06. | Gain Therapeutics, Inc.: Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson's Disease | 477 | GlobeNewswire (Europe) | IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26 FDA's decision follows positive Phase 1 results for GT-02287 in both healthy... ► Artikel lesen | |
| 25.06. | Gain Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| GAIN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 10.06. | Gain Therapeutics, Inc.: Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit | 2 | GlobeNewswire (USA) | ||
| 27.05. | Oppenheimer bestätigt "Outperform" für Gain Therapeutics | 4 | Investing.com Deutsch | ||
| 27.05. | Gain Therapeutics stock maintained at Outperform by Oppenheimer | 1 | Investing.com | ||
| 26.05. | Gain Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 26.05. | Gain Therapeutics presents phase 1b data on Parkinson's drug | 3 | Investing.com | ||
| 11.05. | Gain Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 11.05. | Gain Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.05. | Gain Therapeutics übertrifft Verlustprognosen - Aktie legt zu | 3 | Investing.com Deutsch | ||
| 11.05. | Gain Therapeutics GAAP EPS of -$0.13 beats by $0.01 | 2 | Seeking Alpha | ||
| 11.05. | Gain Therapeutics, Inc.: Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update | 327 | GlobeNewswire (Europe) | BETHESDA, Md., May 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the... ► Artikel lesen | |
| 24.04. | Gain Therapeutics, Inc.: Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026 | 3 | GlobeNewswire (USA) | ||
| 26.03. | Gain Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 26.03. | Gain Therapeutics GAAP EPS of -$0.61 beats by $0.03 | 2 | Seeking Alpha |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 0,580 | +1,05 % | Inovio Pharmaceuticals, Inc.: INOVIO Announces Pricing of $20.0 Million Public Offering | PLYMOUTH MEETING, Pa., July 29, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing... ► Artikel lesen | |
| INFLARX | 1,585 | -0,69 % | InflaRx N.V.: InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones | Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; clinical preparations ongoing as plannedInitiated feasibility assessment for broadened strategy for... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,300 | -0,39 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates | Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of MedicineAnticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S.... ► Artikel lesen | |
| IBIO | 1,264 | +3,27 % | iBio, Inc.: iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer | SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary... ► Artikel lesen | |
| IMMUNITYBIO | 6,550 | -0,76 % | IBRX Q2 Earnings & Sales Beat Estimates on Strong Anktiva Uptake | ||
| IMMATICS | 8,280 | +2,92 % | Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026 | Houston, Texas and Tuebingen, Germany, July 17, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen | |
| MANNKIND | 3,540 | 0,00 % | H.C. Wainwright reiterates Buy rating on MannKind stock at $10 | ||
| IMMUNIC | 13,180 | +6,59 % | EQS-News: Immunic AG: Immunic to Participate in Investor Conferences in July | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Investor Conferences in July
09.07.2026 / 12:30 CET/CEST
The issuer is solely responsible for... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 5,500 | +0,36 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates | U.S. Amtagvi Revenue Reaches ~$91M and Total Revenue Increased 66% Year-over-Year Gross Margin Increased to 56% Fast Track Designation (FTD) Granted by the FDA for Lifileucel in Soft Tissue Sarcomas... ► Artikel lesen | |
| MOLECULIN BIOTECH | 0,409 | -0,10 % | Moleculin Biotech, Inc.: Moleculin Announces Pricing of $9.3 Million Public Offering | HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announced the pricing of a best-efforts public offering of an aggregate of... ► Artikel lesen | |
| GENPREX | 4,300 | +0,70 % | Genprex, Inc.: Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies | Collaboration Advances Biomarker-Driven Patient Selection and Precision Medicine in Oncology
Validation Studies Aim to Optimize Clinical Trial Patient Selection... ► Artikel lesen | |
| BIOAGE LABS | 10,200 | +0,39 % | BioAge Labs, Inc.: BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates | First participant dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic biomarkers; topline data anticipated in the second half of... ► Artikel lesen | |
| MESOBLAST | 1,380 | +1,36 % | Mesoblasts führende Zelltherapie erzielt im ersten vollständigen Verkaufsjahr einen Umsatz von 115 Mio. US-Dollar | ||
| MACROGENICS | 3,360 | -4,00 % | MacroGenics, Inc.: MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026 | Interim Phase 1 results accepted for poster presentation at ESMO Congress 2026Achieved pre-specified Stage 1 response threshold in squamous cell carcinoma of the head and neck (SCCHN) cohort and enrolling... ► Artikel lesen | |
| KARYOPHARM | 1,740 | -4,40 % | Karyopharm Therapeutics Inc.: Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer | - The Trial Did Not Meet the Primary Endpoint of Progression-Free Survival (PFS) -
- A Trend Favoring the Selinexor Arm was Observed with a 5.3 Month Improvement... ► Artikel lesen |
Das Unternehmen GAIN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,820 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GAIN THERAPEUTICS INC finden Sie auf Wallstreet Online.